Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.

BACKGROUND AND OBJECTIVES Buprenorphine/naloxone (BUP-NX) and methadone are used to treat opioid use disorder (OUD), yet there is insufficient evidence on the impact of doses on interventions' effectiveness and safety when treating OUD attributable to other opioids than heroin. METHODS We explored associations between methadone and BUP-NX doses and treatment outcomes using data from OPTIMA, a 24-week, pragmatic, open-label, multicenter, pan-Canadian, randomized controlled, two-arm parallel trial with participants (N = 272) with OUD who primarily use opioids other than heroin. Participants were randomized to receive flexible take-home BUP-NX (n = 138) or standard supervised methadone treatment (n = 134). We examined associations between highest BUP-NX and methadone doses, and (1) percentage of opioid-positive urine drug screens (UDS); (2) retention in the assigned treatment; and (3) adverse events (AEs). RESULTS The mean (SD) highest BUP-NX and methadone dose were 17.31 mg/day (8.59) and 67.70 mg/day (34.70). BUP-NX and methadone doses were not associated with opioid-positive UDS percentages or AEs. Methadone dose was associated with higher retention in treatment (odds ratio [OR]: 1.025; 95% confidence interval [CI]: 1.010; 1.041), while BUP-NX dose was not (OR: 1.055; 95% CI: 0.990; 1.124). Higher methadone doses (70-110 mg/day) offered higher odds of treatment retention. DISCUSSION AND CONCLUSION Methadone dose was associated with higher retention, which may be related to its full µ-opioid receptor agonism. Future research should notably ascertain the effect of pace of titration on a wide range of outcomes. SCIENTIFIC SIGNIFICANCE Our results extend previous findings of high doses of methadone increasing retention to be applied in our population using opioids other than heroin, including highly potent opioids.

[1]  S. Nielsen,et al.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids. , 2022, The Cochrane database of systematic reviews.

[2]  T. Wild,et al.  Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. , 2022, The American journal of psychiatry.

[3]  D. Panagiotoglou,et al.  Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials , 2022, PloS one.

[4]  S. Springer,et al.  Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community , 2022, Addiction Science & Clinical Practice.

[5]  P. Kurdyak,et al.  The Impact of the COVID-19 Pandemic on Opioid-Related Harm in Ontario , 2021 .

[6]  C. Wessel,et al.  Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review , 2021, Journal of General Internal Medicine.

[7]  F. Tiberg,et al.  Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data , 2020, Drug development and industrial pharmacy.

[8]  D. Ciccarone.  The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. , 2019, The International journal on drug policy.

[9]  O. Amram,et al.  Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. , 2018, Drug and alcohol dependence.

[10]  J. Rehm,et al.  Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. , 2018, Drug and alcohol dependence.

[11]  E. Wood,et al.  The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. , 2018, Contemporary clinical trials.

[12]  Evan Wood,et al.  Management of opioid use disorders: a national clinical practice guideline , 2018, Canadian Medical Association Journal.

[13]  C. Wilder,et al.  Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. , 2017, Journal of substance abuse treatment.

[14]  Jenna L. McCauley,et al.  Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update. , 2015, American Journal of Psychiatry.

[15]  Ayman Fareed,et al.  Effect of Buprenorphine Dose on Treatment Outcome , 2012, Journal of addictive diseases.

[16]  S. Sonne,et al.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. , 2011, Archives of general psychiatry.

[17]  Y. Bao,et al.  A Meta-Analysis of Retention in Methadone Maintenance by Dose and Dosing Strategy , 2009, The American journal of drug and alcohol abuse.

[18]  Gary M. Pollack,et al.  Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective , 2008, The AAPS Journal.

[19]  J. Rehm,et al.  Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. , 2008, Drug and alcohol review.

[20]  Declan T. Barry,et al.  Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients , 2007, Journal of General Internal Medicine.

[21]  W. Ling,et al.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. , 2014, Addiction.

[22]  P. Whelan,et al.  Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds , 2012, Journal of neurosciences in rural practice.